Published in J Immunol on June 24, 2009
The Trypanosoma cruzi flagellum is discarded via asymmetric cell division following invasion and provides early targets for protective CD8⁺ T cells. Cell Host Microbe (2014) 1.48
Transmission and epidemiology of zoonotic protozoal diseases of companion animals. Clin Microbiol Rev (2013) 1.23
Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine. PLoS Pathog (2012) 1.07
TLR9 signaling is required for generation of the adaptive immune protection in Cryptococcus neoformans-infected lungs. Am J Pathol (2010) 1.06
Immune Evasion Strategies of Trypanosoma cruzi. J Immunol Res (2015) 0.95
Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge. Infect Immun (2011) 0.94
Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen. Nat Commun (2013) 0.88
Evasion of the Immune Response by Trypanosoma cruzi during Acute Infection. Front Immunol (2016) 0.84
Nonimmune Cells Contribute to Crosstalk between Immune Cells and Inflammatory Mediators in the Innate Response to Trypanosoma cruzi Infection. J Parasitol Res (2011) 0.84
Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling. Infect Immun (2010) 0.83
Importance of TLR2 on hepatic immune and non-immune cells to attenuate the strong inflammatory liver response during Trypanosoma cruzi acute infection. PLoS Negl Trop Dis (2010) 0.83
Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines. Biomatter (2013) 0.82
A soluble factor from Trypanosoma cruzi inhibits transforming growth factor-ß-induced MAP kinase activation and gene expression in dermal fibroblasts. PLoS One (2011) 0.82
CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development? Mediators Inflamm (2014) 0.80
CD8+ T cells in Trypanosoma cruzi infection. Semin Immunopathol (2015) 0.80
Inhibitory effects of Trypanosoma cruzi sialoglycoproteins on CD4+ T cells are associated with increased susceptibility to infection. PLoS One (2013) 0.80
CpG and interleukin-15 synergize to enhance IFN-γ production by activated CD8+ T cells. Biomed Res Int (2012) 0.78
CD8(+) T Cell Responses to Plasmodium and Intracellular Parasites. Curr Immunol Rev (2013) 0.76
Chagasic patients are able to respond against a viral antigen from influenza virus. BMC Infect Dis (2012) 0.76
Concomitant Benznidazole and Suramin Chemotherapy in Mice Infected with a Virulent Strain of Trypanosoma cruzi. Antimicrob Agents Chemother (2015) 0.76
Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz (2015) 0.76
Rapid Functional Decline of Activated and Memory Graft-versus-Host-Reactive T Cells Encountering Host Antigens in the Absence of Inflammation. J Immunol (2015) 0.75
The Role of Sialic Acid-Binding Receptors (Siglecs) in the Immunomodulatory Effects of Trypanosoma cruzi Sialoglycoproteins on the Protective Immunity of the Host. Scientifica (Cairo) (2013) 0.75
Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps. Adv Parasitol (2016) 0.75
Regional variation in the correlation of antibody and T-cell responses to Trypanosoma cruzi. Am J Trop Med Hyg (2014) 0.75
Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells. Infect Immun (2016) 0.75
Evasion and Immuno-Endocrine Regulation in Parasite Infection: Two Sides of the Same Coin in Chagas Disease? Front Microbiol (2016) 0.75
CD8+ T cell immune response against non-viral pathogens. Semin Immunopathol (2015) 0.75
A Heuristic method for assigning a false-discovery rate for protein identifications from Mascot database search results. Mol Cell Proteomics (2005) 2.52
PCNA ubiquitination and REV1 define temporally distinct mechanisms for controlling translesion synthesis in the avian cell line DT40. Mol Cell (2008) 2.29
Deubiquitination of FANCD2 is required for DNA crosslink repair. Mol Cell (2007) 2.11
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med (2008) 2.04
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93
Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol (2003) 1.88
Epigenetic instability due to defective replication of structured DNA. Mol Cell (2010) 1.86
Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis (2004) 1.79
In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis (2010) 1.72
Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis (2009) 1.62
Vertebrate DNA damage tolerance requires the C-terminus but not BRCT or transferase domains of REV1. Nucleic Acids Res (2005) 1.56
Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol (2006) 1.51
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis (2008) 1.46
Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun (2002) 1.45
Chromosome level assembly of the hybrid Trypanosoma cruzi genome. BMC Genomics (2009) 1.42
Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol (2014) 1.42
CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol (2009) 1.36
The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi. BMC Genomics (2009) 1.33
Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol (2005) 1.33
New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis (2013) 1.23
Role for RAD18 in homologous recombination in DT40 cells. Mol Cell Biol (2006) 1.19
HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop Dis (2008) 1.19
Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity (2012) 1.19
Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence. J Immunol (2009) 1.12
Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in Trypanosoma cruzi strains revealed by array comparative genomic hybridization. BMC Genomics (2011) 1.09
Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi. BMC Microbiol (2009) 1.07
Eliminating Chagas disease: challenges and a roadmap. BMJ (2009) 1.06
Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol (2008) 1.05
A systematic review of high quality diagnostic tests for Chagas disease. PLoS Negl Trop Dis (2012) 1.05
CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance. J Immunol (2010) 1.02
Cutting edge: dysfunctional CD8+ T cells reside in nonlymphoid tissues during chronic Trypanosoma cruzi infection. J Immunol (2003) 1.02
Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov (2011) 0.98
Microarray profiling of gene expression during trypomastigote to amastigote transition in Trypanosoma cruzi. Mol Biochem Parasitol (2003) 0.98
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine (2003) 0.96
Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease. PLoS One (2012) 0.95
Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge. Infect Immun (2011) 0.94
MicroRNA regulation of lymphocyte tolerance and autoimmunity. J Clin Invest (2015) 0.92
TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection. Eur J Immunol (2007) 0.91
Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA. Expert Opin Drug Discov (2011) 0.90
A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi. Genome Biol (2007) 0.90
Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice. Infect Immun (2004) 0.89
Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in Trypanosoma cruzi persistence. Mol Microbiol (2013) 0.89
Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen. Nat Commun (2013) 0.88
TcruziDB: an integrated Trypanosoma cruzi genome resource. Nucleic Acids Res (2004) 0.88
An integrated nano-scale approach to profile miRNAs in limited clinical samples. Am J Clin Exp Immunol (2012) 0.87
Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina. Microbes Infect (2010) 0.85
Timing matters: error-prone gap filling and translesion synthesis in immunoglobulin gene hypermutation. Philos Trans R Soc Lond B Biol Sci (2009) 0.83
Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling. Infect Immun (2010) 0.83
Multidimensional analysis of the insoluble sub-proteome of Oceanobacillus iheyensis HTE831, an alkaliphilic and halotolerant deep-sea bacterium isolated from the Iheya ridge. Proteomics (2007) 0.82
Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge. PLoS Negl Trop Dis (2011) 0.80
Transgenic parasites accelerate drug discovery. Trends Parasitol (2012) 0.80
Multidimensional proteomic analysis of the soluble subproteome of the emerging nosocomial pathogen Ochrobactrum anthropi. J Proteome Res (2006) 0.80
A combined shotgun and multidimensional proteomic analysis of the insoluble subproteome of the obligate thermophile, Geobacillus thermoleovorans T80. J Proteome Res (2006) 0.78
Analysis of DNA replication damage bypass and its role in immunoglobulin repertoire development. Subcell Biochem (2006) 0.77
Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. Bioorg Med Chem (2010) 0.77